Monroe becomes 4th county to use needle exchange
To launch a needle exchange program, community officials must convince the state it has a hepatitis C or HIV outbreak.
Diseases
Articles
New psych hospital in Indy marks break with ‘failing model’
The Pence administration’s decision to spend $120 million on a new psychiatric hospital represents a stark shift from the state’s approach to mental health of the past 30 years.
Eli Lilly ends development of promising insulin drug
Eli Lilly said Friday that it decided to stop developing the insulin peglispro after learning that it would take more time and cost more than expected to understand a significant side effect.
SMARTT: Health disparities among Amos’ many causes
Before his untimely death, Amos Brown used his media pulpit to raise awareness among minority populations about their elevated risks of heart disease, diabetes and stroke.
Sandra Eskenazi donates $5M toward brain initiative
Sandra is the daughter of Sidney and Lois Eskenazi, the couple who provided a $40 million gift to the Eskenazi Health Capital Campaign and for whom the Eskenazi Health system is named.
Governor weighs in on criticism of HPV vaccine letter
The Indiana State Department of Health sent letters to 305,000 parents who haven’t vaccinated their children for a virus known to cause cervical cancer. Conservative groups have objected to what they call an intrusion into parenting decisions.
Lilly competitor fails to win FDA backing for diabetes treatment
AstraZeneca Plc didn’t receive U.S. approval for a new diabetes treatment that combines two of its existing drugs. The combination would have competed with Glyxambi from Lilly.
Settlement clears way for Lilly to launch once-a-day insulin
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
The Interview Issue: Dr. Kent Brantly
Dr. Kent Brantly, who contracted Ebola during a medical mission to Africa, says his faith “motivates everything about who I am.”
Lilly’s heart study sets up showdown with Novo’s Victoza
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Jardiance study lifts Lilly shares to 15-year high
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
Lilly shares jump on latest data from diabetes drug
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.
Novo Nordisk buying 2 DiMarchi-launched drug firms
Calibrium LLC and MB2 LLC, both based in Carmel, have agreed to be sold for undisclosed amounts. They were developing diabetes drugs discovered by the research team of Richard DiMarchi, a chemistry professor at Indiana University.
Lilly shares jump after positive study of diabetes drug
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
Financial planning especially tricky for those with special-needs children
Many parents of children with special needs have to choose between working to help cover added expenses or unemployment so they can tend to their child full time. Financial planning is vital for these families, parents and special-needs advocates said.
Study shows Lilly’s Alzheimer’s drug has small but lasting benefit
New data released Wednesday morning suggest that Eli Lilly and Co.’s Alzheimer’s drug has a modest but lasting impact on the memory-sapping disease. But analysts worry the impact is too small to be meaningful.
Lilly partner Immunocore raises record $320 million
Immunocore Ltd., which this week achieved the biggest private fundraising by a European biotechnology firm in 10 years, plans to accelerate development of its cancer therapy using the money and seek expedited approval.
Clot risk in Lilly lung-cancer drug raises FDA concerns
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
Lilly buoyed by string of positive results from drug trials
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Startup aims to upend diabetes care with matchstick-size implant
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.